Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

The National Institute for Health and Care Excellence (NICE) invited the manufacturer of lenalidomide (Celgene) to submit evidence of the clinical and cost effectiveness of the drug for treating adults with myelodysplastic syndromes (MDS) associated with deletion 5q cytogenetic abnormality, as part...

Descripción completa

Detalles Bibliográficos
Autores principales: Blommestein, Hedwig M., Armstrong, Nigel, Ryder, Steve, Deshpande, Sohan, Worthy, Gill, Noake, Caro, Riemsma, Rob, Kleijnen, Jos, Severens, Johan L., Al, Maiwenn J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706836/
https://www.ncbi.nlm.nih.gov/pubmed/26314282
http://dx.doi.org/10.1007/s40273-015-0318-3

Ejemplares similares

Ejemplares similares